Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,704 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunoglobulin G4-related disease with several inflammatory foci.
Sakamaki A, Kamimura K, Shioji K, Sakurada J, Nakatsue T, Wada Y, Imai M, Mizuno K, Yamamoto T, Takeuchi M, Sato Y, Kobayashi M, Naito M, Narita I, Aoyagi Y. Sakamaki A, et al. Among authors: imai m. Intern Med. 2013;52(4):457-62. doi: 10.2169/internalmedicine.52.9239. Epub 2013 Feb 15. Intern Med. 2013. PMID: 23411701 Free article.
Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment.
Ishikawa T, Imai M, Owaki T, Sato H, Nozawa Y, Sano T, Iwanaga A, Seki K, Honma T, Yoshida T. Ishikawa T, et al. Among authors: imai m. Intern Med. 2018 Oct 1;57(19):2843-2845. doi: 10.2169/internalmedicine.0621-17. Epub 2018 May 18. Intern Med. 2018. PMID: 29780129 Free PMC article.
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Hiraoka A, Kumada T, Kudo M, Hirooka M, Koizumi Y, Hiasa Y, Tajiri K, Toyoda H, Tada T, Ochi H, Joko K, Shimada N, Deguchi A, Ishikawa T, Imai M, Tsuji K, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). Hiraoka A, et al. Among authors: imai m. Dig Dis. 2017;35(6):602-610. doi: 10.1159/000480256. Epub 2017 Oct 17. Dig Dis. 2017. PMID: 29040999 Clinical Trial.
[Unresectable combined hepatocellular-cholangiocellular carcinoma treated with transcatheter arterial chemoembolization and gemcitabine: a case study].
Sano T, Ishikawa T, Imai M, Owaki T, Sato H, Nozawa Y, Iwanaga A, Seki K, Honma T, Yoshida T, Nishikura K, Ishihara N, Kamimura T. Sano T, et al. Among authors: imai m. Nihon Shokakibyo Gakkai Zasshi. 2018;115(12):1069-1077. doi: 10.11405/nisshoshi.115.1069. Nihon Shokakibyo Gakkai Zasshi. 2018. PMID: 30531113 Japanese.
Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study.
Ishikawa T, Imai M, Kamimura H, Tsuchiya A, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Kamimura T. Ishikawa T, et al. Among authors: imai m. World J Gastroenterol. 2007 Nov 7;13(41):5465-70. doi: 10.3748/wjg.v13.i41.5465. World J Gastroenterol. 2007. PMID: 17907289 Free PMC article. Clinical Trial.
1,704 results